Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL54 in Adult PKU Patients
NCT07672756Phase 1Recruiting
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PL54 in phenylketonuria (PKU), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoint: Adverse Events. Started Jul 2025; status: recruiting.
02
Drugs
PL54
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07672756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672756.